Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Heterologous immunity provides a potent barrier to transplantation tolerance
Andrew B. Adams, … , Rafi Ahmed, Christian P. Larsen
Andrew B. Adams, … , Rafi Ahmed, Christian P. Larsen
Published June 15, 2003
Citation Information: J Clin Invest. 2003;111(12):1887-1895. https://doi.org/10.1172/JCI17477.
View: Text | PDF
Article

Heterologous immunity provides a potent barrier to transplantation tolerance

  • Text
  • PDF
Abstract

Many strategies have been proposed to induce tolerance to transplanted tissue in rodents; however, few if any have shown equal efficacy when tested in nonhuman primate transplant models. We hypothesized that a critical distinction between specific pathogen-free mice and nonhuman primates or human patients is their acquired immune history. Here, we show that a heterologous immune response — specifically, virally induced alloreactive memory — is a potent barrier to tolerance induction. A critical threshold of memory T cells is needed to promote rejection, and CD8+ “central” memory T cells are primarily responsible. Finally, treatment with deoxyspergualin, an inhibitor of NF-κB translocation, together with costimulation blockade, synergistically impairs memory T cell activation and promotes antigen-specific tolerance of memory. These data offer a potential explanation for the difficulty encountered when inducing tolerance in nonhuman primates and human patients and provide insight into the signaling pathways essential for memory T cell activation and function.

Authors

Andrew B. Adams, Matthew A. Williams, Thomas R. Jones, Nozomu Shirasugi, Megan M. Durham, Susan M. Kaech, E. John Wherry, Thandi Onami, J. Gibson Lanier, Kenneth E. Kokko, Thomas C. Pearson, Rafi Ahmed, Christian P. Larsen

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Analysis of viral- and allo-specific responses in vivo. B6 mice were inf...
Analysis of viral- and allo-specific responses in vivo. B6 mice were infected with either LCMV, VV, or VSV. The results are displayed for the peak of the response as well as during the memory phase (more than 6 weeks). For comparison, the response to a skin allograft is also shown. (a) Representative dot plots displaying the number of CD8+ IFN-γ+ T cells representing the antiviral response (LCMV-NP396-404, VV-infected stimulators, VSV-N-peptide; left panels) and the corresponding heterologous allo-specific responses (right panels). (b) The number of virus-specific (NP396-404, filled squares) and virally induced, alloreactive T cells (H-2d stimulated, filled triangles) after LCMV infection are shown over time. The allo-specific response after skin graft is shown for comparison (H-2d stimulated, open squares; CD8+, upper panel; CD4+, lower panel). Each time point represents the average for three animals. Experiments were repeated three times with similar results.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts